UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 49

Sortiert nach

Protective Role of Kallistatin in Vascular and Organ Injury

Hypertension (Dallas, Tex. 1979), 2016-09, Vol.68 (3), p.533-541

2016

Volltextzugriff (PDF)

Kallistatin reduces vascular senescence and aging by regulating microRNA‐34a‐SIRT1 pathway

Aging cell, 2017-08, Vol.16 (4), p.837-846

2017

Volltextzugriff (PDF)

Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing

Biological chemistry, 2010-04, Vol.391 (4), p.345-355

2010

Volltextzugriff (PDF)

Intermedin is a new angiogenic growth factor

American journal of physiology. Heart and circulatory physiology, 2009-09, Vol.297 (3), p.H1040-H1047

2009

Volltextzugriff (PDF)

Tissue Kallikrein-Modified Mesenchymal Stem Cells Provide Enhanced Protection Against Ischemic Cardiac Injury After Myocardial Infarction

Circulation Journal, 2013, Vol.77(8), pp.2134-2144

2013

Volltextzugriff (PDF)

Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress

American Journal of Physiology - Renal Physiology, 2008-12, Vol.295 (6), p.F1735-F1743

2008

Volltextzugriff (PDF)

Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery

Human gene therapy, 2006-05, Vol.17 (5), p.545

2006

Volltextzugriff (PDF)

Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats

American journal of physiology. Heart and circulatory physiology, 2003-10, Vol.285 (4), p.H1479-H1488

2003

Volltextzugriff (PDF)

Kallistatin inhibits TGF-β-induced endothelial–mesenchymal transition by differential regulation of microRNA-21 and eNOS expression

Experimental cell research, 2015-09, Vol.337 (1), p.103-110

2015

Volltextzugriff (PDF)

Kallikrein-kinin in stem cell therapy

World journal of stem cells, 2014-09, Vol.6 (4), p.448-457

2014

Volltextzugriff (PDF)

Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis

Experimental cell research, 2016-01, Vol.340 (2), p.305-314

2016

Volltextzugriff (PDF)

Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis

Immunology, 2014-06, Vol.142 (2), p.216-226

2014

Volltextzugriff (PDF)

Identification of a Major Heparin-binding Site in Kallistatin

The Journal of biological chemistry, 2001-01, Vol.276 (2), p.1276-1284

2001

Volltextzugriff (PDF)

Kallistatin antagonizes Wnt/β-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6

Molecular and cellular biochemistry, 2013-07, Vol.379 (1-2), p.295-301

2013

Volltextzugriff (PDF)

Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling

American journal of physiology. Heart and circulatory physiology, 2010-11, Vol.299 (5), p.H1419-H1427

2010

Volltextzugriff (PDF)

Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling

American journal of physiology. Renal physiology, 2012-10, Vol.303 (8), p.F1230-F1238

2012

Volltextzugriff (PDF)

Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis

Critical care (London, England), 2015-05, Vol.19 (1), p.200-200, Article 200

2015

Volltextzugriff (PDF)

Kallistatin reduces vascular senescence and aging by regulating micro RNA ‐34a‐ SIRT 1 pathway

Aging cell, 2017-08, Vol.16 (4), p.837-846

2017

Volltextzugriff (PDF)

Kallistatin inhibits TGF-[beta]-induced endothelial-mesenchymal transition by differential regulation of microRNA-21 and eNOS expression

Experimental cell research, 2015-09, Vol.337 (1), p.103

2015

Volltextzugriff (PDF)

The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction

Biological chemistry, 2006-06, Vol.387 (6), p.665-675

2006

Volltextzugriff (PDF)

Novel Role of Kallistatin in Vascular Repair by Promoting Mobility, Viability, and Function of Endothelial Progenitor Cells

Journal of the American Heart Association, 2014-09, Vol.3 (5), p.e001194-n/a

2014

Volltextzugriff (PDF)

Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis

Nephrology, dialysis, transplantation, 2006-03, Vol.21 (3), p.624-633

2006

Volltextzugriff (PDF)

Kallistatin antagonizes Wnt/[beta]-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6

Molecular and cellular biochemistry, 2013-07, Vol.379 (1-2), p.295

2013

Volltextzugriff (PDF)

Role of Tissue Kallikrein in Prevention and Recovery of Gentamicin-Induced Renal Injury

Toxicological sciences, 2008-04, Vol.102 (2), p.433-443

2008

Volltextzugriff (PDF)

Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation

American Journal of Physiology - Renal Physiology, 2010-04, Vol.298 (4), p.F1033-F1040

2010

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(45)

Publikationsform

Sprache

Englisch
(49)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(32)
Life Sciences & Biomedicine
(28)
Animals
(22)
Humans
(18)
Male
(16)
Rats
(13)
Biological And Medical Sciences
(10)
Oxidative Stress
(10)
Apoptosis
(8)
Disease Models, Animal
(8)
Physiology
(8)
Rodents
(8)
Angiogenesis
(7)
Cardiovascular System & Cardiology
(7)
Fibrosis
(7)
Fundamental And Applied Biological Sciences. Psychology
(7)
Gene Expression
(7)
Inflammation
(7)
Nitric Oxide
(7)
Blood Urea Nitrogen
(6)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Protective Role of Kallistatin in Vascular and Organ Injury

Kallistatin reduces vascular senescence and aging by regulating microRNA‐34a‐SIRT1 pathway

Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing

Intermedin is a new angiogenic growth factor

Tissue Kallikrein-Modified Mesenchymal Stem Cells Provide Enhanced Protection Against Ischemic Cardiac Injury After Myocardial Infarction

Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress

Reversal of renal fibrosis, inflammation, and glomerular hypertrophy by kallikrein gene delivery

Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats

Kallistatin inhibits TGF-β-induced endothelial–mesenchymal transition by differential regulation of microRNA-21 and eNOS expression

Kallikrein-kinin in stem cell therapy

Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis

Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis

Identification of a Major Heparin-binding Site in Kallistatin

Kallistatin antagonizes Wnt/β-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6

Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling

Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling

Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis

Kallistatin reduces vascular senescence and aging by regulating micro RNA ‐34a‐ SIRT 1 pathway

Kallistatin inhibits TGF-[beta]-induced endothelial-mesenchymal transition by differential regulation of microRNA-21 and eNOS expression

The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction

Novel Role of Kallistatin in Vascular Repair by Promoting Mobility, Viability, and Function of Endothelial Progenitor Cells

Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis

Kallistatin antagonizes Wnt/[beta]-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6

Role of Tissue Kallikrein in Prevention and Recovery of Gentamicin-Induced Renal Injury

Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation

Suchergebnisse filtern